Skip to main content
Clinical Trials/JPRN-UMIN000010957
JPRN-UMIN000010957
Completed
未知

Investigation of anti-tumoral effect and safety of combination therapy LD-GP (low dose gemcitabine and paclitaxel) therapy and sorafenib in patients with cisplatin-resistant advanced urothelial cancer. - Efficacy and safety of combination therapy of low dose gemcitabine and paclitaxeltherapy with sorafenib in patients with cisplatin-resistant urothelial cancer.

agasaki University Hospital0 sites15 target enrollmentJune 16, 2013

Overview

Phase
未知
Intervention
Not specified
Conditions
Cisplatin-resistant urothelial cancer
Sponsor
agasaki University Hospital
Enrollment
15
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 16, 2013
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
agasaki University Hospital

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Blood examinations WBC: under 3,000 / mm3\. Neut: under 1,500 / mm3\. Plt: under 100,000/ mm3\. Hgb: under 8 g/dl. T\-Bil: over 1\.5 mg/dl. s\-Cr: over 2\.0 mg/dl.

Outcomes

Primary Outcomes

Not specified

Similar Trials